2011
DOI: 10.1016/j.mehy.2011.03.047
|View full text |Cite
|
Sign up to set email alerts
|

Is Gilbert Syndrome a new risk factor for breast cancer?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2013
2013
2021
2021

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(4 citation statements)
references
References 18 publications
0
4
0
Order By: Relevance
“…It is possible that estrogen (moreso in female animals) competes with bilirubin for glucuronidation by UGT1A1 [60], elevating bilirubin concentration [15], with bilirubin exerting an effect on cholesterol homeostasis. It is also equally possible that bilirubin competes with estrogen for conjugation [60], elevating estrogen concentrations [81]. Circulating estrogen levels in Gunn rats/Gilbert's syndrome have not yet been reported, however, could partly explain alterations in lipid status [82].…”
Section: Gunn Rat Modelmentioning
confidence: 99%
“…It is possible that estrogen (moreso in female animals) competes with bilirubin for glucuronidation by UGT1A1 [60], elevating bilirubin concentration [15], with bilirubin exerting an effect on cholesterol homeostasis. It is also equally possible that bilirubin competes with estrogen for conjugation [60], elevating estrogen concentrations [81]. Circulating estrogen levels in Gunn rats/Gilbert's syndrome have not yet been reported, however, could partly explain alterations in lipid status [82].…”
Section: Gunn Rat Modelmentioning
confidence: 99%
“…[8] Also, higher risk for breast [9] and colorectal [10] cancers has been reported in GS, most probably as a result of carcinogens detoxification decrease [11,12] and estrogen-related disease. [13] …”
Section: Introductionmentioning
confidence: 99%
“…32 Apparently for UGT1A1 gene pathological allele (TA)7 carriers, the predisposition to oncogenesis is a consequence of a decrease in the carcinogens detoxification 12,21 and altered of estrogen levels. 33 In particular, the TATAA box polymorphism of the UGT1A1 is a risk factor for benz(a)pyrene (BaP) metabolite-induced carcinogenesis. 12 Another example of the UGT1A1 *28 polymorphism negative impact is an increased risk of bronchopulmonary dysplasia developing and an increased mortality of premature infants from respiratory diseases.…”
Section: Discussionmentioning
confidence: 99%